阿尔茨海默病中的微细胞-神经元交叉:对分子机制和病理影响的探索
Xizhen Kang1, Jun Tian1, Qing Shu1
1Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Neuroscience
|July 12, 2025
概括
微质和神经元通信中断导致阿尔茨海默病 (AD) 的进展. 针对这些相互作用,为神经退行症和保持大脑健康提供了新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 微质细胞是中枢神经系统 (CNS) 的免疫细胞.
- 神经元是中枢神经系统中的主要信息传递器.
- 中枢神经系统中的平衡依赖于微质神经元相互作用.
研究的目的:
- 在阿尔茨海默病 (AD) 中审查微质神经元相互作用的分子机制.
- 探索如何打断通信有助于AD的发病因子.
- 为了确定AD的潜在治疗点.
主要方法:
- 对AD中微质-神经元通信的当前文献的综述.
- 分析涉及交叉通话的分子通路.
- 讨论针对这些相互作用的治疗策略.
主要成果:
- 在AD中中断的微质神经元交叉涉及神经递质信号传递,突触消除,分子分泌和直接细胞接触.
- 功能障碍的沟通导致微质过度活化,氧化应激,加速记忆丧失和神经炎症.
- 涉及到TREM2,补充级联和炎症酶等特定途径.
结论:
- 了解微质-神经元交叉交互对于开发有效的AD疗法至关重要.
- 针对特定的途径可能会阻止神经退行,同时保持免疫功能.
- 先进的技术,如时空奥米克和实时成像,可以跟踪这些相互作用,并识别治疗窗口.
相关概念视频
01:26Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263